[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fibrotic-interstitial-lung-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fibrotic-interstitial-lung-disease":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,67,103,128,159],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":66},"100630072","optimizing-the-diagnostic-journey-in-interstitial-lung-disease-the-optimize-ild-1-trial-100630072",false,"NCT07482917","Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 Trial","OPTIMIZE-ILD-1: A Randomized, Pragmatic, Parallel-Group Trial Evaluating the Impact of an Optimized Diagnostic Circuit on Time to Diagnosis in Patients With Suspected Interstitial Lung Disease","OPTIMIZE-ILD-1","Inclusion Criteria:\n\n* Age 18 years or older.\n* Referral for suspected or undiagnosed interstitial lung disease (ILD).\n* At least one of the following:\n\n  * A finding suggestive of ILD (such as reticulation, ground-glass opacities, traction bronchiectasis or honeycombing) not attributable to another disease, on a CT available at referral that includes the lung parenchyma, regardless of its indication; or\n  * Persistent or progressive shortness of breath or chronic cough not attributable to another disease, accompanied by at least one of the following: an interstitial or reticular pattern on chest radiograph; reduced forced vital capacity; persistent bibasilar crackles or digital clubbing; a relevant environmental or occupational exposure, autoimmune disease, or suspected drug or radiation toxicity; or a first-degree family history of ILD.\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Complete ILD diagnostic work-up already performed (chest CT plus full pulmonary function testing including six-minute walk test plus complete ILD laboratory panel).\n* Established diagnosis of ILD previously assigned by another center or specialist.\n* Clinical instability or acute illness that would prevent reliable completion of diagnostic procedures (e.g., respiratory infection, suspected acute ILD exacerbation, acute heart failure).\n* Acute iatrogenic pneumonitis (drug-, chemotherapy- or radiation-induced) with a clear temporal relationship to the offending agent.\n* Medical, functional, psychiatric or logistical limitations that, in the investigators' opinion, would interfere with the diagnostic process or data collection.\n* Participation in another interventional clinical trial that may alter the frequency or timing of diagnostic procedures.\n* Cognitive impairment that prevents informed consent or completion of study questionnaires.\n* Refusal to participate or to allow the collection or use of clinical data.","ALL","18 Years",{"count":20,"type":21},92,"ESTIMATED","INTERVENTIONAL",[24],"NA","The OPTIMIZE-ILD-1 trial is a prospective, randomized, open-label clinical trial designed to evaluate the impact of a coordinated diagnostic pathway on patients with suspected interstitial lung disease (ILD). In routine clinical practice, diagnostic workflows for ILD are frequently fragmented, involving multiple independent appointments that can lead to significant delays and increased burden for patients and caregivers. This study compares the standard diagnostic pathway against an optimized circuit where core diagnostic procedures-such as high-resolution CT, pulmonary function tests, and laboratory panels-are pre-bundled and scheduled within a coordinated and compressed timeframe.\n\nAll eligible patients referred for suspected ILD are included consecutively to ensure a pragmatic, real-world representation of the referral population. The primary objective is to measure the time to diagnostic communication, defined as the duration from randomization to the date the patient is formally informed of the final diagnosis following a multidisciplinary team (MDT) consensus. Secondary objectives include assessing the time to MDT diagnosis, the time to treatment initiation (when clinically indicated), socioeconomic cost-burden, and the environmental carbon footprint of the diagnostic journey. Furthermore, the study evaluates health-related quality of life, psychological distress, and clinical frailty, while exploring factors such as language proficiency as determinants of diagnostic equity. Caregiver-related outcomes, including burden and experience measures, are contingent upon the presence of a primary caregiver and the provision of their independent informed consent.\n\nThe design of this protocol was informed by a patient focus group and is officially endorsed by the 'AIRE' Associació Catalana de Malalts i Trasplantats Pulmonars, ensuring a patient-centered approach that prioritizes the diagnostic journey's efficiency and human impact.",[27,28,29,30,31],"Interstitial Lung Disease (ILD)","Suspected Interstitial Lung Disease","Fibrotic Interstitial Lung Disease","Idiopathic Pulmonary Fibrosis (IPF)","Interstitial Lung Disease Due to Connective Tissue Disease (Disorder)",[33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53],"Interstitial Lung Disease","ILD","Suspected ILD","Pulmonary Fibrosis","Idiopathic Pulmonary Fibrosis","Connective Tissue Disease-ILD","IPF","Diagnostic Pathway","Diagnostic Delay","Multidisciplinary Discussion","One-Day ILD Clinic","Time to Diagnosis","Time to Treatment Initiation","Organizational Intervention","Health Services Research","Diagnostic Workflow Optimization","Patient Experience","Quality of Life","Pulmonary Function Tests","High-Resolution CT","Carbon Footprint","RECRUITING","2026-06-30",{"date":57,"type":58},"2026-07-02","ACTUAL",{"date":60,"type":58},"2026-03-09",{"date":62,"type":21},"2028-03-01",{"name":64,"class":65},"Hospital de Granollers","OTHER",1,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":76,"briefSummary":77,"conditions":78,"keywords":81,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":66},"100644762","remote-evaluation-and-surveillance-of-patients-with-interstitial-lung-disease-transforming-ild-care-delivery-with-remote-monitoring-100644762","NCT07673237","Remote Evaluation and Surveillance of Patients With Interstitial Lung Disease: Transforming ILD Care Delivery With Remote Monitoring","RESPOND-ILD","Inclusion Criteria:\n\n* age 18 or older\n* English or Spanish speaking\n* have a UCSF diagnosis of one of the major ILD subtypes seen in the ILD Clinic (Idiopathic Pulmonary Fibrosis, Chronic Hypersensitivity Pneumonitis, Connective-tissue disease related ILD, Sarcoidosis, Familial Fibrosis). Languages are limited to those for which both device instructional materials and user support are available (written and video). The ILD diagnosis will be based on multidisciplinary conference review, which is the diagnostic gold standard. We have restricted the ILD subtypes to those for which there is efficacy data for RPM or comparable clinical trajectories, and subtypes that account for \\>10% of the ILD diagnoses seen at UCSF.\n\nExclusion Criteria:\n\n* Patients who are unable provide informed consent for any reason or are acutely ill.",{"count":75,"type":21},200,[24],"The purpose of this interventional study is to identify which combination of remote monitoring devices (e.g. home spirometry, pulse oximetry, scale, ePROs) is the most feasible (as defined by adherence, retention, and data completeness) and acceptable when used for the detection of clinically significant Interstitial Lung Disease events.",[29,79,80],"IPF and PPF","Lung Fibrosis Interstitial",[82,83,84,85,86,87,88,89,90,91,92],"Interstitial lung disease","pulmonary fibrosis","idiopathic pulmonary fibrosis","progressive pulmonary fibrosis","Remote patient monitoring","Digital health","Telemonitoring","Home monitoring","Pragmatic study design","Real-world monitoring","Decentralized clinical trial","NOT_YET_RECRUITING","2026-06-22",{"date":96,"type":58},"2026-06-29",{"date":98,"type":21},"2026-08-01",{"date":100,"type":21},"2028-08-01",{"name":102,"class":65},"University of California, San Francisco",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":114,"conditions":115,"keywords":116,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":66},"100520176","phase-2-ambulatory-oxygen-therapy-for-individuals-with-mild-to-moderate-interstitial-lung-disease-100520176","NCT06053164","Ambulatory Oxygen Therapy for Individuals With Mild-to-moderate Interstitial Lung Disease","Inclusion Criteria:\n\n* Individuals with fibrotic ILD (all sub-groups of ILD) who have normal oxygen saturation at rest (SpO2 \\> 90%) but develop exertional hypoxemia as demonstrated by a SpO2 = 80-89% with activity (measured during 6MWT).\n\nExclusion Criteria:\n\n* Use of home oxygen therapy within the previous year for the management of ILD, co-morbid conditions that may require oxygen therapy (such as COPD, cardiovascular disease, or other illnesses), or individuals that require the use of non-invasive ventilation. Additionally, individuals with significant cardiovascular, metabolic, neuromuscular or any other disease that could contribute to dyspnea or abnormal cardiopulmonary responses to exercise will be excluded. Individuals with musculoskeletal injuries that prevent them from completing cycle ergometry exercise trials and ambulation will also be excluded. Individuals with peripheral vascular disease will be excluded from measurement of vascular function (flow mediated dilation).","85 Years",{"count":111,"type":21},60,[113],"PHASE2","The investigators plan to conduct a study to find out if giving portable oxygen therapy (during physical activity) to patients with interstitial lung disease will improve quality of life, exercise tolerance, shortness of breath, and blood vessel function. Oxygen will be provided for a period of 8 weeks. Additionally, the investigators plan to investigate if it is helpful to deliver individualized support when providing oxygen therapy, through check-in phone calls with a respiratory therapist and by providing additional educational material.",[29],[117,118,33],"Exertional Oxygen","Ambulatory Oxygen","2026-06-02",{"date":121,"type":58},"2026-06-04",{"date":123,"type":58},"2025-07-01",{"date":125,"type":21},"2026-09-01",{"name":127,"class":65},"University of Alberta",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":138,"briefSummary":139,"conditions":140,"keywords":142,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":157,"leadSponsor":158,"locationsCount":66},"100630325","optimizing-the-follow-up-journey-in-interstitial-lung-disease-the-optimize-ild-2-trial-100630325","NCT07486206","Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial","OPTIMIZE-ILD-2: A Randomized, Pragmatic, Parallel-Group Trial Evaluating the Impact of an Optimized Coordinated Follow-Up Circuit on Time Burden in Patients With Interstitial Lung Disease","OPTIMIZE-ILD-2","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Established diagnosis of interstitial lung disease (ILD).\n* Currently receiving antifibrotic therapy, immunosuppressive therapy, or both, as part of routine ILD care.\n* Under active follow-up at the participating ILD center.\n* Able to attend the required follow-up procedures included in the study visit.\n* Able to provide informed consent.\n\nExclusion Criteria:\n\n* Inability to complete the coordinated follow-up visit for non-medical reasons (e.g., logistical impossibility).\n* Clinical instability or acute illness interfering with planned follow-up procedures (such as respiratory infection, suspected ILD exacerbation, acute heart failure, or other acute conditions).\n* Participation in another interventional clinical trial that may alter visit frequency or follow-up structure.\n* Cognitive impairment preventing informed consent or completion of questionnaires.\n* Patient refusal to participate or refusal to allow data collection.",{"count":137,"type":21},152,[24],"The OPTIMIZE-ILD-2 trial is a prospective, randomized, open-label clinical trial designed to evaluate the impact of a coordinated follow-up pathway on patients with established interstitial lung disease (ILD). In routine clinical practice, follow-up workflows for ILD are frequently fragmented, requiring multiple hospital visits for pulmonary function tests, laboratory analysis, treatment administration, and consultations with various specialists, which increases the burden for both patients and caregivers. This study compares the standard follow-up care against an optimized circuit where all routine monitoring procedures and interdisciplinary consultations are pre-bundled and scheduled within a single, coordinated hospital visit.\n\nAll eligible patients under active ILD follow-up are included consecutively to ensure a pragmatic, real-world representation of the treated ILD population. The primary objective is to measure the total follow-up time burden, defined as the total home-to-home time required to complete the follow-up circuit. As a cross-sectional assessment within a longitudinal context, secondary objectives include assessing socioeconomic cost-burden, the environmental carbon footprint of the follow-up journey, health-related quality of life, and clinical frailty. Caregiver-related outcomes, including burden and experience measures, are contingent upon the presence of a primary caregiver and the provision of their independent informed consent.\n\nThe design of this protocol was informed by a patient focus group and is officially endorsed by the 'AIRE' Associació Catalana de Malalts i Trasplantats Pulmonars, ensuring a patient-centered approach that prioritizes follow-up efficiency and human impact.",[27,29,30,141,31],"Progressive Pulmonary Fibrosis",[33,34,36,37,141,143,144,145,146,147,148,149,150,43,47,151,46,51,50,49,53,152],"CTD-ILD","Fibrotic ILD","Antifibrotic Therapy","Immunosuppressive Therapy","Follow-Up Pathway","Follow-Up Care Coordination","Time Burden","Home-to-Home Time Burden","Patient-Centered Follow-Up","Multidisciplinary Care","2026-04-06",{"date":155,"type":58},"2026-04-09",{"date":60,"type":58},{"date":62,"type":21},{"name":64,"class":65},{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":17,"minAge":166,"maxAge":109,"enrollmentInfo":167,"targetDuration":4,"studyType":22,"phases":169,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":4},"100603845","phase-4-efficacy-and-safety-of-early-antifibrotic-therapy-for-non-progressive-fibrotic-interstitial-lung-disease-100603845","NCT07141810","Efficacy and Safety of Early Antifibrotic Therapy for Non-progressive Fibrotic Interstitial Lung Disease","Early Antifibrotic Therapy for f-ILD","Inclusion Criteria:\n\n1\\) Able to understand the procedures and methods of this study, willing to strictly follow the clinical trial protocol to complete this study, and sign the informed consent; 2) The age of signing the informed consent is 40-85 years old (including both ends of the value); 3) Weight: male ≥50 kg, female ≥40 kg; 4) During screening, FVC accounted for more than 45% of the estimated value and 90%; 5) The percentage of pulmonary carbon monoxide dispersion (DLCO) to the predicted value (corrected by Hb value) during screening was ≥30% and ≤90%; 6) Diagnosed with fibrotic ILD: In the past 12 months, at least 3 months after basic treatment such as glucocorticoids and immunosuppressants, reexamination of chest CT showed fibrotic features such as diffuse mesh shadow, honeycomb lung, and tractive bronchiectasis in both lungs, and the lesions could not be further absorbed.\n\n\\-\n\nExclusion Criteria:\n\n1. Patients with unstable disease (IPF) assessed by investigators during screening had acute exacerbations during screening or within 3 months before randomization;\n2. Patients who are likely to require lung transplantation within 6 months or whose expected survival is less than 1 year as assessed by the investigators at the time of screening;\n3. During screening, chest HRCT indicated that the range of emphysema exceeded the range of pulmonary fibrosis (based on independent imaging evaluation results);\n4. Patients with airway obstruction disease (such as FEV1\u002FFVC after bronchodilator);\n5. Diagnosed with IPF\n6. Diagnosis of PPF according to the 2022 ATS\u002FERS\u002FJRS\u002FALAT guidelines\n7. Patients with other types of respiratory diseases that the investigators assessed might affect the study results;\n8. Patients who need to receive oxygen therapy for 15 hours or more per day;\n9. Resting pulse oxygen \\\u003C 90% (sea level to 1500m above sea level) or \\\u003C 85% (altitude \\> 1500m) when breathing indoor air during screening;\n10. with other poorly controlled underlying conditions (such as NYHA Class III or IV congestive heart failure, acute myocardial infarction, unstable angina, hemorrhagic or ischemic stroke, pulmonary hypertension requiring treatment within the 6 months prior to screening), Patients assessed by the investigator as unsuitable for the study;\n11. Patients who had an active tuberculosis infection in the 12 months prior to screening, or had a bacterial, viral, fungal, or microbial infection requiring treatment with any clinical symptoms within the 4 weeks prior to randomization;\n12. Patients diagnosed with NCOV infection 1 month before screening and\u002For during screening (NCOV nucleic acid testing is not part of this study and can be performed on demand);\n13. Patients who plan to receive NCOV vaccine and other vaccines from 1 month before screening to 1 month after the last dose;\n14. Patients with a history of malignant tumors (except cured basal cell carcinoma of the skin and cervical carcinoma in situ) within 5 years prior to screening, or who are currently being evaluated for potential malignant tumors;\n15. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥2 upper limit of normal (ULN) or total bilirubin ≥1.5× upper limit of normal (ULN);\n16. Serum creatinine ≥1.5× upper limit of normal (ULN);\n17. Active hepatitis, syphilis or HIV antibody positive patients;\n18. Major surgery (general anesthesia) within 3 months prior to screening, or surgery planned to be performed during the study period that the investigator assessed would affect the study endpoint;\n19. Participated in any clinical trial (including other investigational drug\u002Finvestigational device therapy) within 3 months prior to screening, or was still within 5 half-lives of the investigational drug at the time of screening;\n20. Current smoking history, smoking cessation ≤3 months, or unable to abstain from smoking for the entire study period;\n21. Suspected or confirmed history of alcohol or drug abuse;\n22. Known allergy to the investigational drug and its ingredients;\n23. Pregnant and lactating women, female subjects who plan to become pregnant during the study period, or patients who do not wish to use contraceptives that meet the protocol requirements during the trial;\n24. Other conditions assessed by the investigator as unsuitable for participation in the study.","40 Years",{"count":168,"type":21},104,[170],"PHASE4","Early antifibrotic therapy for f-ILD",[29],"2025-08-24",{"date":175,"type":58},"2025-08-26",{"date":177,"type":21},"2025-10-01",{"date":179,"type":21},"2028-05-30",{"name":181,"class":65},"Shanghai Pulmonary Hospital, Shanghai, China"]